Skip to content

Clinical study of cholesterol metabolism and high-density lipoprotein function in patients with abnormal thyroid function

Clinical study of cholesterol metabolism and high-density lipoprotein function in patients with abnormal thyroid function

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OOC-14005549
Enrollment
Unknown
Registered
2014-11-25
Start date
2014-12-15
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

thyroid dysfunctional disease

Interventions

Healthy:No
hyperthyroidism group:No
hypothyroidism:No
Subclinical hyperthyroidism:No
Subclinical hypothyroidism:No

Sponsors

Taishan Medical Universisty
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 60 Years

Inclusion criteria

Inclusion criteria: The normal range of Thyroid hormone: TSH 0.35-4.94uIU/ml; FT3 1.45-3.48pg/ml; FT4 0.71-1.85pg/ml; Hyperthyroidism: FT3 more than 3.48pg/ml and/or FT4 more 1.85pg/ml and TSH less than 4.94uIU/ml; Hypothyroidism: FT3 less than 3.48pg/ml and/or FT4 less than 1.85pg/ml and TSH more than 4.94uIU/ml; Subclinical hyperthyroidism: FT3 1.45-3.48pg/ml and FT4 0.71-1.85pg/ml and TSH less than 4.94uIU/ml; Subclinical hypothyroidism: FT3 1.45-3.48pg/ml and FT4 0.71-1.85pg/ml and TSH more than 4.94uIU/ml.

Exclusion criteria

Exclusion criteria: Familial hypercholesterolemia, Secondary hyperlipidemia, Smoking, Drinking, Diabetes, Use of Statin.

Design outcomes

Primary

MeasureTime frame
Plasma total cholesterol;Plasma low-density lipoprotein cholesterol;Plasma high-density lipoprotein cholesterol;Triglyceride;Plasma apolipoprotein B level;Plasma apolipoprotein AI level;Plasma apolipoprotein E level;Plasma high-density lipoprotein function;

Countries

China

Contacts

Public ContactShucun Qin
shucunqin@hotmail.com+86 13583815481

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026